Atherosclerosis core

动脉粥样硬化核心(核心3；C3)将由Edward Fisher博士领导，并提供计划项目赠款 (PPG)研究人员使用三种互补的方法分析动脉粥样硬化病变、病变 巨噬细胞，以及在髓系细胞和组织中的基因表达。首先，C3将 提供动脉粥样硬化病变的组织学染色、免疫组织化学和定量。其次，它将 提供对动脉粥样硬化病变中巨噬细胞和其他类型细胞的激光捕获显微解剖 分析基因表达的变化。第三，C3将提供主动脉消化方面的专业知识，以获得特定的细胞 将样本提供给纽约大学基因组技术中心(GTC)进行RNA测序(RNA- SEQ)和单细胞RNA-SEQ(scRNA-SEQ)分析。然后，这些“组学”数据将经过生物信息学 核心1下的分析，将监督行政、数据管理、生物统计和 生物信息学。通过提供中央实验室，C3以最优的效率和成本提供这些服务- 有效性，避免了PPG调查人员自己维护所需的仪器 实验室或使用昂贵的商业服务。通过集中和标准化程序，C3提供了 一套通用的分析工具，使人们能够统一理解 动脉粥样硬化的病理生理过程以及巨噬细胞和内皮细胞的生物学。这个 C3的具体目标是：1.提供全面的组织分析和动脉粥样硬化的量化 提供靶细胞的激光捕获显微切割(LCM)，主要是巨噬细胞 动脉粥样硬化病变用于基因表达研究；3.制备主动脉组织(通过消化和流式细胞仪)以 向GTC提供RNA-seq和scRNA-seq的样本(结果数据将由核心1进行分析)。

The Atherosclerosis Core (Core 3; C3) will be led by Dr. Edward Fisher and provide Program Project Grant (PPG) investigators with three complementary approaches for analyzing atherosclerotic lesions, lesion macrophages, and gene expression in myeloid cells and tissues investigated in the projects. First, C3 will provide histological staining, immunohistochemistry, and quantification of atherosclerotic lesions. Second, it will provide laser capture microdissection of macrophages and other types of cells in atherosclerotic lesions for analysis of gene expression changes. Third, C3 will provide expertise in aortic digestion to obtain specific cell compartments to provide samples to the NYU Genomic Technology Center (GTC) for RNA sequencing (RNA- seq) and single cell RNA-seq (scRNA-seq) analyses. These `omic' data will then undergo bioinformatic analyses under Core 1, which will oversee Administration, Data Management, Biostatistics, and Bioinformatics.By providing a central laboratory, C3 offers these services with optimal efficiency and cost- effectiveness, avoiding the need for PPG investigators to maintain the required instrumentation in their own laboratories or use expensive commercial services. By centralizing and standardizing procedures, C3 provides a common set of analytical tools to enable a unified understanding of molecular mechanisms involved in pathophysiologic processes of atherosclerosis and the biology of macrophages and endothelial cells. The Specific Aims of C3 are: 1. To provide comprehensive tissue analysis and quantification of atherosclerotic lesions; 2. To provide laser capture microdissection (LCM) of target cells, primarily macrophages, in atherosclerotic lesions for gene expression studies; 3. To prepare aortic tissue (by digestion and FACS) to provide samples to the GTC for RNA-seq and scRNA-seq (with the resulting data to be analyzed by Core 1).